LUPIN - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 4.1
| Stock Code | LUPIN | Market Cap | 1,02,897 Cr. | Current Price | 2,252 ₹ | High / Low | 2,378 ₹ |
| Stock P/E | 18.6 | Book Value | 596 ₹ | Dividend Yield | 0.53 % | ROCE | 21.9 % |
| ROE | 17.8 % | Face Value | 2.00 ₹ | DMA 50 | 2,233 ₹ | DMA 200 | 2,096 ₹ |
| Chg in FII Hold | 1.00 % | Chg in DII Hold | -0.98 % | PAT Qtr | 1,241 Cr. | PAT Prev Qtr | 869 Cr. |
| RSI | 45.8 | MACD | 21.9 | Volume | 3,89,299 | Avg Vol 1Wk | 7,30,226 |
| Low price | 1,774 ₹ | High price | 2,378 ₹ | PEG Ratio | 0.11 | Debt to equity | 0.04 |
| 52w Index | 79.1 % | Qtr Profit Var | 18.6 % | EPS | 120 ₹ | Industry PE | 27.2 |
📊 Analysis: Lupin (LUPIN) demonstrates strong fundamentals with ROE (17.8%) and ROCE (21.9%), supported by robust earnings growth. The stock trades at a P/E of 18.6, below the industry average of 27.2, making it attractively valued. The PEG ratio of 0.11 suggests excellent growth potential relative to valuation. Dividend yield of 0.53% provides modest income support. Quarterly PAT improved significantly (1,241 Cr vs 869 Cr), highlighting operational strength. Technical indicators (RSI 45.8, MACD 21.9) show neutral-to-bullish momentum, with price above both 50 DMA (2,233 ₹) and 200 DMA (2,096 ₹).
💡 Entry Price Zone: Ideal entry would be in the 2,100–2,200 ₹ range, close to the 200 DMA, offering strong value relative to fundamentals.
📈 Exit Strategy: If already holding, consider a long-term horizon (3–5 years) given strong ROE/ROCE and undervaluation compared to peers. Partial profit booking can be considered near 2,350–2,400 ₹ resistance levels, but long-term compounding potential justifies holding.
✅ Positive
- Strong ROE (17.8%) and ROCE (21.9%) support long-term growth.
- Low P/E (18.6) compared to industry average (27.2).
- PEG ratio of 0.11 indicates excellent valuation-to-growth alignment.
- Quarterly PAT growth (43%) highlights operational strength.
- Debt-to-equity ratio at 0.04 reflects a near debt-free balance sheet.
⚠️ Limitation
- Dividend yield is modest (0.53%), limiting income appeal.
- DII holdings decreased (-0.98%), showing reduced domestic institutional confidence.
📉 Company Negative News
- DII stake reduction indicates cautious sentiment from domestic institutions.
- Stock trading near recent highs may limit immediate upside.
📈 Company Positive News
- Quarterly PAT improved (1,241 Cr vs 869 Cr previous quarter).
- EPS at 120 ₹ reflects strong earnings power.
- FII holdings increased (+1.00%), showing foreign investor confidence.
🏭 Industry
- Pharma sector trades at higher average PE (27.2), making Lupin undervalued.
- Industry growth supported by global demand for generics and specialty drugs.
🔎 Conclusion
Lupin is fundamentally strong, attractively valued, and positioned for long-term growth. Long-term investors should consider entry around 2,100–2,200 ₹ for optimal risk-reward. Existing holders are advised to maintain positions for 3–5 years to benefit from compounding, with partial exits near resistance levels. Lupin is a solid candidate for long-term investment.